QMBlog Content
Discover More:
// December 27, 2023
Drivers of global health impact in 2024
Our global health impact goes beyond just numbers to improve millions of lives. Learn why 2023 was such a pivotal year and what’s next in 2024.
// December 08, 2023
Revisiting the Landscape of Potential Nitrosamines in Pharmaceuticals using CPCA fram...
Quality Matters recently sat down with USP Principal Scientist Naiffer Romero, who has teamed up with researchers at LHASA Limited, AstraZeneca, Sai Life Sciences and Merck for collaborative research on nitrosamine impurities. In Part One of this series, we discussed the new research. Here’s Part Two.
// November 28, 2023
FDA's Draft Guidance for Topical Ophthalmic Drug Products: USP Standards ...
This year has seen a flurry of activity by the U.S. Food and Drug Administration surrounding ophthalmic products.
// November 27, 2023
Building a More Resilient Medicines Supply Chain
Building a More Resilient Medicines Supply Chain
In this Q&A with the Duke-Margolis Drug Supply Chain Resilience and Advanced Manufacturing Consortium, US Pharmacopeia (USP) policy expert Amy B. Cadwallader highlights the importance of multi-disciplinary, cross-functional coordination to strengthen the medicine supply chain and global public health resilience in the face of ongoing threats, like persistent drug shortages. This Q&A was first published in the Consortium's eNewsletter and is re-printed with the permission of the Duke-Margolis Center for Health Policy.